(Q37671041)

English

Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report

scientific article published on January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report (English)

1 reference

Europe PubMed Central

21 August 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Petra Schnell-Inderst

1

object named as

Petra Schnell-Inderst

0 references

author name string

Ruth Schwarzer

2

1 reference

Europe PubMed Central

21 August 2017

Alexander Göhler

3

1 reference

Europe PubMed Central

21 August 2017

Norma Grandi

4

1 reference

Europe PubMed Central

21 August 2017

Kristin Grabein

5

1 reference

Europe PubMed Central

21 August 2017

Björn Stollenwerk

6

1 reference

Europe PubMed Central

21 August 2017

Jennifer Manne

7

1 reference

Europe PubMed Central

21 August 2017

Volker Klauss

8

1 reference

Europe PubMed Central

21 August 2017

Uwe Siebert

9

1 reference

Europe PubMed Central

21 August 2017

Jürgen Wasem

10

1 reference

Europe PubMed Central

21 August 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

21 August 2017

International Journal of Technology Assessment in Health Care

1 reference

Europe PubMed Central

21 August 2017

26

1 reference

Europe PubMed Central

21 August 2017

1

1 reference

Europe PubMed Central

21 August 2017

30-39

1 reference

Europe PubMed Central

21 August 2017

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Use and misuse of the receiver operating characteristic curve in risk prediction

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Understanding articles describing clinical prediction tools. Evidence Based Medicine in Critical Care Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Inflammation and atherosclerosis: role of C-reactive protein in risk assessment

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Expanding the orbit of primary prevention--moving beyond JUPITER.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice ...

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929)

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing New Biomarkers and Predictive Models for Use in Clinical Practice

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990870

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S0266462309990870

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37671041&oldid=2131345030"